Russia's Pharmsynthez buys Estonian pharma firm and extends production
This article was originally published in Scrip
Executive Summary
St-Petersburg-based Pharmsynthez is buying the Estonian pharmaceutical company, Kevelt. No financial details have been revealed, but Russian experts estimated that the deal could be worth anywhere between few tens and two hundred million roubles (up to $7 million).